Aims and objectives

The ESCMID Study Group for Non-Traditional Antibacterial Therapy (ESGNTA) brings together professionals from various expertise dedicated to advancing the use of bacteriophages and other new non-traditional therapeutic approaches to treat infectious diseases. Our mission includes: 

  • Developing microbiological guidelines and supporting the clinical use of phages and phage-derived products, via clinical trials and compassionate use
  • Identifying bacterial pathogens and infectious disease indications where non-traditional antibacterials, including bacteriophage therapies, may lead to cure or improved clinical outcomes
  • Increasing knowledge and fostering research on phage-derived enzymes, especially lysins, to identify the optimal carriers and applications in clinical settings, such as gels and nanoparticles
  • Creating a network and promoting the establishment of academic phage therapy centres across European countries, based on the models developed in Belgium, France, Israel, Australia, and the USA

Activities and resources

ESGNTA Newsletter, Spring 2024, April 2024 

Download


ESGNTA Newsletter, Spring 2024, March 2024 

Download


ESGNTA Newsletter, Winter 2023, February 2023 

Download


ESGNTA Newsletter, Spring 2023, April 2023 

Download


ESGNTA Newsletter, Summer 2023, August 2023

Download


ESGNTA Newsletter, Autumn 2023, November 2023

Phages and phage-borne enzymes as new antibacterial agents. 

McCallin S, Drulis-Kawa Z, Ferry T, Pirnay JP, Nir-Paz R. Clin Microbiol Infect. 2023;20:S1198-743X(23)00528-1.

Go to publication


Personalized Phage Therapy: Basic Principles of monitoring and treatment: Supplement 5 1 Nov 2023 

Nir-Paz R, Iredell J, Suh G, Fabijan AP. Clinical Infectious Diseases, Vol 77, Issue Supplement 5, 1 November 2023.

Go to publication

Global Clinical Phage Rounds 8 

Lessons learned (so far) from treating patients with phage therapy for antibiotic-resistant bacterial infections


Global Clinical Phage Rounds 7 

Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter


Global Clinical Phage Rounds 6 

The French Experience


Global Clinical Phage Rounds 5 

Case Discussion – How long is enough: duration of phage therapy for NTM infections in three Australian patients?


Global Clinical Phage Rounds 4 

Belgian Published cases


Global Clinical Phage Rounds 3 

Case Discussion – Urgent cases on Mycobacterium


Global Clinical Phage Rounds 2 

Case Discussion – Renal transplant and recurrent UTIs

ESGNTA as part of the VOM2023 conference 

7 July 2023, The George Eliava Institute of Bacteriophages, Tbilisi, Georgia Congress

Go to course


Personalized phage therapy: from the lab to the patient 

Technical workshop

Go to course

Executive Committee

  Ran Nir-Paz

Ran Nir-Paz

Chairperson
Hadassah-Hebrew University Medical Center. Clinical Microbiology and infectious Diseases
Jerusalem, Israel
  Zuzanna Drulis-Kawa

Zuzanna Drulis-Kawa

Treasurer
University of Wroclaw. Department of Pathogen Biology and Immunology
Wroclaw
  Shawna McCallin

Shawna McCallin

Secretary
Balgrist University Hospital. Neuro-Urology
Zurich, Switzerland
  Jean-Paul Pirnay

Jean-Paul Pirnay

Science Officer
Queen Astrid Military Hospital. LabMCT
Brussels, Belgium
  Tristan Ferry

Tristan Ferry

Education Officer/Clinical Officer
Hospices Civils de Lyon. Infectious Diseases
Lyon, France

Contact

If you have questions or comments for our study group, we warmly invite you to contact us!

Contact form